Mass Tort brief
Bellwether Reckonings Test Pharma, Tech, and Chemical Exposure
Federal MDL dockets accelerate across medical devices, algorithmic harm, and toxic exposure as judges press for definitive trial verdicts.
Mass Tort
J&J's $5.5B talc deal hinges on a near-unanimous claimant vote that warring plaintiff firms could easily derail to pursue individual jury trials.
BackgroundTens of thousands of plaintiffs allege cosmetic talc distributed by Johnson & Johnson was contaminated with carcinogenic asbestos fibers that caused ovarian cancer and mesothelioma. Federal bankruptcy courts previously threw out two consecutive corporate attempts to resolve those liabilities through controversial divisional bankruptcies.
- The proposed structure disburses up to $3 billion in initial claimant distributions starting in 2027, with the remainder funded in subsequent installments over several years.
- Plaintiffs' steering committees remain fractured, with rival legal factions disputing voting procedures and the adequacy of financial payouts for terminal mesothelioma victims.
- Attaining the mandatory 95% affirmative claimant threshold represents a formidable hurdle given ongoing disputes among personal injury law firms competing over fee allocations.
Mass Tort
Mass Tort
A second straight defense verdict would crush plaintiffs' settlement leverage — but a plaintiff win forces Teva to fund a multi-million-dollar global resolution.
BackgroundMultidistrict litigation consolidates thousands of personal injury claims before one judge to coordinate discovery and conduct bellwether test trials. These representative jury verdicts give both sides concrete valuation ranges needed to negotiate global settlements.
- Robere v. Teva opened before US District Judge Leigh Martin May, focusing on design-defect and failure-to-warn theories regarding brittle plastic arm fractures that lodge in uterine tissue.
- The trial follows a February 2026 defense verdict in the first test case, making a plaintiff win essential to avoid collapsing settlement pressure on Teva.
- More than 4,180 consolidated personal injury cases assert that broken copper fragments require invasive surgical removals and cause permanent scarring and reproductive injury.
Mass Tort
Expanding GLP-1 suits from stomach paralysis into sudden blindness transforms manageable gastrointestinal side-effect claims into catastrophic bodily injury liability for drugmakers.
BackgroundGlucagon-like peptide-1 receptor agonists are widely prescribed for chronic obesity and type 2 diabetes management, generating tens of billions in annual pharmaceutical sales. The federal multidistrict litigation in Pennsylvania initially focused on stomach paralysis before expanding into permanent vision loss.
- Lawsuits allege popular semaglutide and tirzepatide injectables trigger ischemic vascular interruptions in the optic nerve head, causing sudden permanent vision loss in one or both eyes.
- Plaintiffs argue manufacturers failed to update product warning labels despite emerging clinical studies and adverse regulatory alerts issued by European health agencies.
- Federal judges are coordinating pretrial expert discovery across parallel gastroparesis and ophthalmic injury dockets ahead of initial bellwether selections expected later this year.
Mass Tort
Mass Tort
Unlock the full brief
Sign in to read every signal, takeaway, and source. Free account — Apple, Google, or email.
